Article 22 Apr 2026 FDA Releases Congressional Justification For FY 2027 Budget, Including Proposal Regarding Interchangeability Of Biosimilars United States Healthcare
Article 14 Apr 2026 Teva Receives FDA Approval Of Denosumab Biosimilar And Filing Acceptances By FDA And EMA For Omalizumab Biosimilar United States Healthcare
Article 08 Jan 2026 Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe European Union Healthcare
Article 31 Dec 2025 CareFirst's Class Action STELARA® Antitrust Case Against J&J Will Proceed: Court Grants-in-Part And Denies-in-Part Class Certification And Denies The Parties' Motions For Summary Judgment United States Anti-trust
Article 29 Dec 2025 Regeneron Seeks To Bifurcate Or Stay Amgen's Antitrust Claims In Aflibercept Patent Litigation United States IP
Article 24 Nov 2025 Regeneron Moves To Strike And Dismiss Amgen's Counterclaims In Aflibercept Litigation United States IP
Article 08 Sep 2025 FDA Approves Denosumab Biosimilars BILDYOS And BILPREVDA United States Healthcare
Article 19 Aug 2025 PTAB Discretionarily Denies Two Petitions, Refers A Third To The Board In Amgen v. Bristol-Myers Squibb United States IP
Article 15 Jul 2025 Denosumab Updates: Wyost And Jubbonti Launch As First Denosumab Biosimilars In The U.S. United States Healthcare
Article 25 Jun 2025 Regeneron Files Another Complaint Against Amgen In Aflibercept BPCIA Litigation United States IP
Article 02 Jun 2025 Biogen Files Suit Against Neurimmune Over Rights To Bispecific Antibody United States Healthcare
Article 22 May 2025 HyClone Seeks To Quash Amgen's Subpoena Issued In Amgen/Accord Denosumab BPCIA Litigation United States IP
Article 30 Apr 2025 Regeneron, Mylan, And Biocon Settle In Aflibercept BPCIA Litigation United States Healthcare
Article 19 Mar 2025 Federal Circuit Affirms Denial Of Injunction Against Amgen In Aflibercept BPCIA Litigation United States IP
Article 11 Mar 2025 Federal Circuit Affirms Injunction Against Celltrion In Aflibercept BPCIA Litigation United States IP